aTyr seeks to develop innovative therapeutics to address the unmet needs of patients by developing a novel class of biologic drugs. We have developed proprietary methods for discovering Physiocrines„¢, extracellular proteins that are derived from the tRNA synthetase family of enzymes, and which were predominantly overlooked by other genomic and secretome discovery efforts. aTyr™s proprietary discovery approach and expertise has enabled the exploration of this completely new class of biologic targets, and has allowed aTyr to establish a unique and comprehensive intellectual property portfolio across the Physiocrine family. We are currently developing a portfolio of Physiocrine therapeutic proteins, and focusing on indications in the areas of hematology, immune modulation, infection, and metabolism.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/29/13 | $10,000,000 | Venture Debt |
Silicon Valley Bank | undisclosed |
| 04/01/15 | $76,000,000 | Series E |
Deerfield Management Company, L.P. EcoR1 Capital Federated Kaufmann Funds Rock Springs Capital Sofinnova Ventures Sphera Global Healthcare T. Rowe Price Associates | undisclosed |
